LB Pharmaceuticals Inc (LBRX)
LBRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | LBRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0001691082 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Recent IPO: no annual report filed yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $215.1M cash; operating cash flow -$35.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 32,363,040 (2026-11-03); 25,299,102 a year earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-10-01 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., New York, New York, United States | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$59.1M | -$64.3M | $215.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$51.6M | -$37.6M | $283.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$19.1M | -$23.3M | $320.7M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | Not filed | -$11.5M | -$18.1M | $250.2M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | Not filed | -$3.6M | -$3.4M | $269.7M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$4.9M | -$5.6M | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2025 2025-03-31 | Not filed | -$5.3M | -$8.1M | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2024 2024-12-31 | Not filed | -$5.1M | -$5.7M | $23.0M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-10-01 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 146 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.4% |
| 1 month | +23.6% |
| 3 months | -2.8% |
| Year to date | +93.2% |
| 1 year | +188.7% |
| From 52-week high | -13.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DMRA | Damora Therapeutics Inc. | $22.50 | +4.14% | $1.4B |
| URGN | UroGen Pharma Ltd. | $28.10 | +7.33% | $1.4B |
| TYRA | Tyra Biosciences Inc. | $19.74 | -1.42% | $1.4B |
| PAHC | Phibro Animal Health Corporation | $35.02 | -2.64% | $1.4B |
| ANAB | AnaptysBio Inc. | $45.73 | -1.12% | $1.4B |
| NUVB | Nuvation Bio Inc. | $3.84 | -3.76% | $1.4B |
| GENB | Generate Biomedicines Inc. | $10.49 | -13.09% | $1.4B |
| NBTX | Nanobiotix S.A. | $28.54 | -6.90% | $1.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier